Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : AnGes
Deal Size : Inapplicable
Deal Type : Inapplicable
Vasomune and AnGes Progress Phase 2a Trial Of AV-001 with High-Dose Cohort
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Inapplicable
December 03, 2024
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : AnGes
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Fast Track To Vasomune's AV-001 Novel Investigational Medicine
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Inapplicable
May 28, 2024
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Inapplicable
November 14, 2023
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Infections and Infectious Diseases
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Inapplicable
December 11, 2020
Lead Product(s) : Vasculotide
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Preclinical
Sponsor : Us Department Of Defense
Deal Size : $2.8 million
Deal Type : Funding
Vasomune Receives a US $2.8 Million PRMRP Grant from the US Department of Defense to Develop AV-001
Details :
Product Name : AV-001
Product Type : Peptide
Upfront Cash : Undisclosed
August 18, 2020
Lead Product(s) : Vasculotide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Preclinical
Sponsor : Us Department Of Defense
Deal Size : $2.8 million
Deal Type : Funding